Keyword: Boehringer Ingelheim
Other bidders may have dropped out of an auction for Sanofi's European generics unit, but that doesn't mean it hasn't found a buyer.
A year after tapping a former Yankees star for its "Breathless" push, Boehringer Ingelheim had another surprise for baseball fans this opening day.
Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.
Boehringer Ingelheim wants to move its drug nintedanib into the scleroderma market. Meanwhile, it’s working to expand awareness of the disease, too.
As Sanofi presses ahead with the sale of its EU generics unit, a private equity firm has reportedly bowed out over price.
Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.
IPF patients often say they don't feel "sick enough" for treatment, so Boehringer is aiming to show doctors the benefits of early intervention.
When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.
Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.
Novo Nordisk's newest Victoza campaign doubles down on its approved trifecta of preventative indications for heart attack, stroke and CV death.
